Form 4 Tracker
Entrada Therapeutics, Inc.
TRDA

21 insider filings · Latest: Aug 6, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Sep 9, 2024Sep 9 8:27 PMKORY WENTWORTH
Proposed Sale
3,195$14.80$47.3K

View →

Sep 6, 2024Sep 6 8:19 PMNATHAN DOWDEN
Proposed Sale
3,150$15.39$48.5K

View →

← Previous

Page 3 of 3

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Jun 10, 2026Jun 12 9:34 PMKush ParmarDirector, 10% Owner
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 9:17 PMPeter S KimDirector
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 9:16 PMGina ChapmanDirector
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 9:05 PMMaha RadhakrishnanDirector
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 9:01 PMMary ThistleDirector
Grant/Award
19,000$5.9719,000(D)

View →

Jun 10, 2026Jun 12 8:52 PMBernhardt G ZeiherDirector
Grant/Award
19,000$5.9719,000(D)

View →

May 4, 2026May 4 11:24 PMNathan J DowdenPresident & COO
Option Exercise
15,000$1.7449,831(D)

View →

Mar 1, 2026Mar 3 11:21 PMDipal DoshiDirector, CEO
Grant/Award
208,000$11.93208,000(D)

View →

Mar 1, 2026Mar 3 11:20 PMKory James WentworthChief Financial Officer
Grant/Award
66,600$11.9366,600(D)

View →

Mar 1, 2026Mar 3 11:19 PMNathan J DowdenPresident & COO
Grant/Award
83,200$11.9383,200(D)

View →

Mar 1, 2026Mar 3 11:18 PMNatarajan SethuramanPresident, Research & Develop.
Grant/Award
83,200$11.9383,200(D)

View →